The FDA has established a strategic plan for encouraging the development of novel treatments for rare diseases that affect pediatric patients. The framework includes greater private-sector engagement, utilization of biomarkers and a faster approval pathway. The idea is to address some of the challenges involved in developing devices and drugs for rare conditions in pediatric patients, including the small number of patients who can take part in trials.

Full Story:
PMLive.com (U.K.)

Related Summaries